These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

172 related items for PubMed ID: 3297203

  • 1. CFU-GM content of bone marrow graft correlates with time to hematologic reconstitution following autologous bone marrow transplantation with 4-hydroperoxycyclophosphamide-purged bone marrow.
    Rowley SD, Zuehlsdorf M, Braine HG, Colvin OM, Davis J, Jones RJ, Saral R, Sensenbrenner LL, Yeager A, Santos GW.
    Blood; 1987 Jul; 70(1):271-5. PubMed ID: 3297203
    [Abstract] [Full Text] [Related]

  • 2. Analysis of factors predicting speed of hematologic recovery after transplantation with 4-hydroperoxycyclophosphamide-purged autologous bone marrow grafts.
    Rowley SD, Piantadosi S, Marcellus DC, Jones RJ, Davidson NE, Davis JM, Kennedy J, Wiley JM, Wingard JR, Yeager AM.
    Bone Marrow Transplant; 1991 Mar; 7(3):183-91. PubMed ID: 2059755
    [Abstract] [Full Text] [Related]

  • 3. Differential sensitivity of adherent CFU-blast, CFU-mix, BFU-E, and CFU-GM to mafosfamide: implications for adjusted dose purging in autologous bone marrow transplantation.
    Carlo-Stella C, Mangoni L, Almici C, Garau D, Craviotto L, Piovani G, Caramatti C, Rizzoli V.
    Exp Hematol; 1992 Mar; 20(3):328-33. PubMed ID: 1568448
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. In vitro sensitivity of human hematopoietic progenitor cells to 4-hydroperoxycyclophosphamide.
    Ratajczak MZ, Ratajczak J, Kuczynski W, Light B, Lusk EJ, Gewirtz AM.
    Exp Hematol; 1993 Dec; 21(13):1663-7. PubMed ID: 8243568
    [Abstract] [Full Text] [Related]

  • 7. Analysis for recovery and loss of mononuclear cells and colony-forming units granulocyte-macrophage during ex vivo processing of autologous bone marrow.
    Schwella N, Heuft HG, Rick O, Blasczyk R, Wittmann G, Huhn D.
    Vox Sang; 1996 Dec; 70(3):132-8. PubMed ID: 8740003
    [Abstract] [Full Text] [Related]

  • 8. Correlation of hematologic recovery with CFU-GM content of autologous bone marrow grafts treated with 4-hydroperoxycyclophosphamide. Culture after cryopreservation.
    Rowley SD, Piantadosi S, Santos GW.
    Bone Marrow Transplant; 1989 Sep; 4(5):553-8. PubMed ID: 2790333
    [Abstract] [Full Text] [Related]

  • 9. GM-CSF therapy for delayed engraftment after autologous bone marrow transplantation.
    Brandwein JM, Nayar R, Baker MA, Sutton DM, Scott JG, Sutcliffe SB, Keating A.
    Exp Hematol; 1991 Mar; 19(3):191-5. PubMed ID: 1995310
    [Abstract] [Full Text] [Related]

  • 10. In vitro sensitivity of post-bone marrow transplantation CFU-GM and BFU-E to TNF-alpha and IFN-gamma.
    Papadakis V, Ferguson KF, Heller G, Kernan NA.
    Exp Hematol; 1995 Dec; 23(14):1422-30. PubMed ID: 8542927
    [Abstract] [Full Text] [Related]

  • 11. In vivo effects of GM-CSF and IL-3 on hematopoietic cell recovery in bone marrow and blood after autologous transplantation with mafosfamide-purged marrow in lymphoid malignancies.
    Albin N, Douay L, Fouillard L, Laporte JP, Isnard F, Lesage S, Ozsahin H, Bardinet D, Najman A, Gorin NC.
    Bone Marrow Transplant; 1994 Aug; 14(2):253-9. PubMed ID: 7994241
    [Abstract] [Full Text] [Related]

  • 12. Variability in 4-hydroperoxycyclophosphamide activity during clinical purging for autologous bone marrow transplantation.
    Jones RJ, Zuehlsdorf M, Rowley SD, Hilton J, Santos GW, Sensenbrenner LL, Colvin OM.
    Blood; 1987 Nov; 70(5):1490-4. PubMed ID: 3311205
    [Abstract] [Full Text] [Related]

  • 13. The use of recombinant cytokines for enhancing immunohematopoietic reconstitution following bone marrow transplantation. II. The influence of lymphokines on CFU-GM colonies from human untreated, ASTA-Z or Campath-1M treated bone marrow.
    Mumcuoglu M, Naparstek E, Slavin S.
    Bone Marrow Transplant; 1990 Mar; 5(3):153-8. PubMed ID: 2184907
    [Abstract] [Full Text] [Related]

  • 14. Use of recombinant human granulocyte-macrophage colony-stimulating factor in patients with lymphoid malignancies transplanted with unpurged or adjusted-dose mafosfamide-purged autologous marrow.
    Carlo-Stella C, Mangoni L, Almici C, Cottafavi L, Meloni G, Mandelli F, Rizzoli V.
    Blood; 1992 Nov 01; 80(9):2412-8. PubMed ID: 1421413
    [Abstract] [Full Text] [Related]

  • 15. Hematopoietic recovery following high-dose combined alkylating-agent chemotherapy and autologous bone marrow support in patients in phase-I clinical trials of colony-stimulating factors: G-CSF, GM-CSF, IL-1, IL-2, M-CSF.
    Laughlin MJ, Kirkpatrick G, Sabiston N, Peters W, Kurtzberg J.
    Ann Hematol; 1993 Dec 01; 67(6):267-76. PubMed ID: 7506580
    [Abstract] [Full Text] [Related]

  • 16. Normal hematopoietic reconstitution following ASTA-Z 7557-purged grafts in the absence of in vitro CFU-GM colony growth.
    Nagler A, Mumcuoglu M, Naparstek E, Or R, Gan S, Slavin S.
    Leuk Res; 1993 Jan 01; 17(1):61-7. PubMed ID: 8429681
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Effects of in vitro purging with 4-hydroperoxycyclophosphamide on the hematopoietic and microenvironmental elements of human bone marrow.
    Siena S, Castro-Malaspina H, Gulati SC, Lu L, Colvin MO, Clarkson BD, O'Reilly RJ, Moore MA.
    Blood; 1985 Mar 01; 65(3):655-62. PubMed ID: 3971044
    [Abstract] [Full Text] [Related]

  • 20. CFU-GEMM correlate with neutrophil and platelet recovery in patients receiving autologous marrow transplantation after high-dose melphalan chemotherapy.
    Roodman GD, LeMaistre CF, Clark GM, Page CP, Newcomb TF, Knight WA.
    Bone Marrow Transplant; 1987 Aug 01; 2(2):165-73. PubMed ID: 3332164
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.